Following the FDA’s September announcement of a crackdown on direct-to-consumer drug marketing practices and the subsequent flurry of untitled and warning letters criticizing dozens of Big Pharma ads, ...
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback